Non-linear pharmacokinetics of ofloxacin after a single intravenous bolus dose in pigs
- PMID: 11107005
- DOI: 10.1046/j.1365-2885.2000.00289.x
Non-linear pharmacokinetics of ofloxacin after a single intravenous bolus dose in pigs
Abstract
The pharmacokinetics of ofloxacin (OFLX) was investigated after intravenous administration of 3, 10 and 30 mg/kg of body weight in pigs. Plasma OFLX concentration-time course collected from the highest dosage showed a convex decline, indicating a capacity-limited process in drug elimination (Michaelis-Menten elimination). Dose-normalized area under curve (AUC/Dose) and mean resident time (MRT) were dose-dependent, indicating a classical pattern of non-linear elimination pharmacokinetics. Based on simultaneous curve fitting from three doses, non-linear pharmacokinetic parameters were as follows: 0.87 mg/h/kg for maximum velocity, 2.20 microg/mL in Michaelis-Menten constant and 2.06 L/kg for apparent volume of distribution. Based on a model-independent analysis, the apparent volume of distribution at steady-state (Vdss) was dose-independent whereas total body clearance (CLtot) was dose-dependent, mainly contributed by renal clearance (CLr) with the regression line of CLtot=1.14xCLr+0.09 (r=0.92). The intercept of the regression line indicates non-renal clearance (CLnr), corresponding to the value of observed CLnr without dose-dependency. Because of a higher CLr compared with glomerular filtration rate (GFR) in spite of drug reabsorption, the CLr must contain the renal active tubular secretion. With increasing dosage, the level of saturation of tubular secretion of OFLX decreased the CLr, resulting in the decrease in CLtot. The plasma protein binding to OFLX was dose-independent: mean free fraction (fp)=0.73, with probably no influential effect on OFLX disposition. In conclusion, the degree of saturation in the renal active tubular secretion of OFLX could be a major causal factor in the alteration of CLr in an increasing dosage of OFLX. Accordingly, the alteration of CLr could directly induce the non-linear pharmacokinetics of OFLX in pigs, an important consideration in clinical therapeutics.
Similar articles
-
The clinical pharmacokinetics of levofloxacin.Clin Pharmacokinet. 1997 Feb;32(2):101-19. doi: 10.2165/00003088-199732020-00002. Clin Pharmacokinet. 1997. PMID: 9068926 Review.
-
Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers.Int J Clin Pharmacol Res. 1991;11(5):203-9. Int J Clin Pharmacol Res. 1991. PMID: 1814841 Clinical Trial.
-
Enantioselective disposition of ofloxacin in humans.Antimicrob Agents Chemother. 1991 Oct;35(10):2106-9. doi: 10.1128/AAC.35.10.2106. Antimicrob Agents Chemother. 1991. PMID: 1759834 Free PMC article.
-
Species-related stereoselective disposition of ofloxacin in the rat, dog and monkey.Xenobiotica. 1992 Apr;22(4):439-50. doi: 10.3109/00498259209046656. Xenobiotica. 1992. PMID: 1523865
-
Ofloxacin pharmacokinetics in chronic renal failure and dialysis.Clin Pharmacokinet. 1991 Nov;21(5):357-71. doi: 10.2165/00003088-199121050-00004. Clin Pharmacokinet. 1991. PMID: 1773550 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources